CoChat

Patients with refractory Crohn's disease or ulcerative colitis respond to dehydroepiandrosterone: a pilot study

Open access
Andus, T., Klebl, F., Rogler, G., Bregenzer, N., Schölmerich, J., Straub, R. H. · 2003 · Alimentary Pharmacology & Therapeutics
Cited by 50

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Abstract

Summary: Background : Dehydroepiandrosterone is a steroid hormone used as an ‘over‐the‐counter’ drug in the USA. Treatment with dehydroepiandrosterone was effective in randomized controlled trials in patients with systemic lupus erythematosus. Dehydroepiandrosterone sulphate concentrations are decreased in patients with inflammatory bowel disease. Dehydroepiandrosterone inhibits nuclear factor‐κB and the secretion of interleukin‐6 and interleukin‐12 via the peroxisome proliferator‐activated receptor α. Aim : A phase II pilot trial was started to evaluate the effect of dehydroepiandrosterone in active inflammatory bowel disease. Methods : Twenty patients with chronic active inflammatory bowel disease [seven Crohn's disease (Crohn's disease activity index, 242 ± 51; mean ± s.d.); 13 ulcerative colitis (clinical activity index, 7.8 ± 2.1)] took 200 mg dehydroepiandrosterone per day orally for 56 days. Results : Six of the seven patients with Crohn's disease and eight of the 13 patients with ulcerative colitis responded to treatment, with a decrease in the Crohn's disease activity index of > 70 points and a decrease in the clinical activity index of > 4 points, respectively. Six Crohn's disease patients and six ulcerative colitis patients went into remission (Crohn's disease activity index < 150; clinical activity index ≤ 4). No patient withdrew from the study because of side‐effects. Conclusions : In a pilot study, dehydroepiandrosterone was effective and safe in patients with refractory Crohn's disease or ulcerative colitis. Adjustment of the dehydroepiandrosterone dosage may further improve the treatment success.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1046/j.1365-2036.2003.01433.x

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Cited by

See all 50

Metadata

Authors
Andus, T., Klebl, F., Rogler, G., Bregenzer, N., Schölmerich, J., & Straub, R. H.
Venue
Alimentary Pharmacology & Therapeutics
Publisher
Wiley
Published
2003-02
Volume
17
Issue
3
Pages
409-414
ISSN
  • 0269-2813 (ISSN-L)
  • 1365-2036
OpenAlex
W1992072556
Cited by
50
References
4
FWCI
2.68
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Patients with refractory Crohn's disease or ulcerative colitis respond to dehydroepiandrosterone: a pilot study. https://app.cochat.ai/papers/10.1046/j.1365-2036.2003.01433.x
The paper
Andus, T., Klebl, F., Rogler, G., Bregenzer, N., Schölmerich, J., & Straub, R. H. (2003). Patients with refractory Crohn's disease or ulcerative colitis respond to dehydroepiandrosterone: a pilot study. Alimentary Pharmacology & Therapeutics. https://doi.org/10.1046/j.1365-2036.2003.01433.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.